![]() is a leading global high-performance analog technology company dedicated to solving the toughest engineering challenges, enabling our customers to interpret the world around us by intelligently bridging the physical and digital with unmatched technologies that sense, measure, power, connect and interpret. Pinpoint's platform-a handheld reader and disposable cartridges-is easy to use and affordable, showing accurate results in under a minute, with no lab, technicians, amplification or sample prep needed. Early targets include influenza, coronavirus, and STDs. Pinpoint's nanosensors are used to detect biomarkers-antibodies, antigens, toxins, nucleic acids-to identify specific microbial pathogens. ![]() is a San Francisco-based startup developing a new generation of bioelectronic point-of-care diagnostics for viral, bacterial and fungal pathogens. We are developing a low-cost, high-speed handheld screening test that can be rapidly deployed as a critical weapon to address emerging global disease threats."Īngelike Kefalas at (415) 606-2900 or ![]() Pinpoint's technology can uniquely address the problem of effective mass screening: sensitive enough to detect asymptomatic infections, specific enough to distinguish novel coronavirus from other illnesses, fast enough to replace fever scans, simple enough to use for home self-testing, and affordable enough to use anywhere in the world. We see the immediate real-world need for our platform, especially with the pandemic threat posed by the novel coronavirus. "Our collaboration with a world-class semiconductor manufacturer like ADI means we can begin to realize the potential of our groundbreaking technology. "We are thrilled to be working with Analog Devices to develop and manufacture our innovative nanosensor diagnostic platform," commented Lisa Diamond, CEO of Pinpoint Science. "Analog Devices believes Pinpoint's novel nanosensor technology holds great promise for a wide range of applications, especially for rapid, low-cost pathogen detection, and we look forward to a long and fruitful collaboration with Pinpoint in bringing this breakthrough technology to market," commented Nimrode Moreshet, Director of Emerging Business at Analog Devices. Other coronavirus diagnostic tests under development don't work for mass screening: they're essential to diagnose suspected cases at the clinic or hospital, but results take anywhere from 15 minutes to 8 hours, too slow for front-line screening.Īnalog Devices has an active interest in advancing nanosensor technology and plans to collaborate with Pinpoint on solutions and product offerings of mutual benefit to both companies. ![]() Today only scanning foreheads for fever is widely used for screening, but this cannot detect asymptomatic or presymptomatic infections, nor can it distinguish the novel coronavirus from other respiratory illnesses. With the threat of the novel Covid-19 coronavirus concerning health officials globally, there is urgent need for better methods of mass screening to contain the spread of the virus. Pinpoint's nanosensors, developed with the advanced fabrication capabilities of ADI, will target low-cost, handheld diagnostics and strive to provide results in under a minute with lab test level accuracy. ![]() Pinpoint Science, a startup based in the San Francisco Bay Area, and Analog Devices will work together to develop and mature this new technology that will endeavor to transform the way infectious diseases are diagnosed around the world. 25, 2020 /PRNewswire/ - Pinpoint Science Inc. today announced a strategic collaboration with Analog Devices, Inc. to advance the development and manufacture of novel nanosensor diagnostics that aim to deliver highly accurate results in under a minute. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |